SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group (CAR) is currently experiencing intense volatility and downward pressure as traders debate whether the stock is undergoing a long-overdue correction following a rapid price surge or a deliberate institutional-led unwind. The community is actively tracking frequent trading halts and divided between those attempting to catch a reversal bounce and others anticipating a return to historical price levels due to underlying fundamental concerns.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing significant volatility and trading volume as investors react to the latest quarterly update, which highlighted progress on the Eagle Line production ramp and new commercial engagements in the AI data center and defense sectors. The stock has become a focal point for intense debate between market participants debating whether these operational milestones signal a long-term turnaround or if the current price action remains driven by speculative short-term trading and potential dilution concerns.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors closely monitor potential data center capacity deals and upcoming energization milestones, while the stock faces significant volatility from market makers and ongoing debates over share dilution. Community sentiment remains polarized between long-term bulls betting on the company's power-secured infrastructure moat and skeptics concerned about management's communication and frequent price reversals.

Applied Digital Corporation

Applied Digital is trending as investors rally behind a new 7.5 billion dollar AI data center lease with a major hyperscaler, significantly expanding the company's contracted revenue backlog. The community is actively debating the potential identity of this new partner, the impact of high short interest on future price action, and the company's long-term growth trajectory within the AI infrastructure sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in this leveraged inverse semiconductor ETF are expressing significant frustration as an unprecedented, multi-week rally in the chip sector continues to erode value and trigger persistent daily losses. The community is actively debating whether this extreme market behavior indicates a bubble fueled by algorithmic manipulation or a genuine, long-term super-cycle in AI-driven demand.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing a parabolic, historic rally driven by intense speculative demand in the semiconductor sector and significant short covering, leading to a heated community debate over whether this represents an unsustainable 'AI bubble' or a new era of market growth. While many bulls are celebrating massive double-digit gains and calling for further upside, bears are warning of an imminent, sharp correction, causing friction and active trading in both the bull and bear leveraged ETFs.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is currently trending due to a surge in market optimism surrounding U.S. federal cannabis rescheduling, which the community sees as a long-awaited catalyst for tax relief and improved banking access. Investors are actively debating the sustainability of this momentum, weighing potential short squeezes and institutional interest against historical patterns of profit-taking and reflexive market volatility.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing intense volatility driven by market skepticism over the appointment of a former Nike executive as the company's new CEO and broader concerns regarding brand saturation and competitive pressure. While some investors view the current low valuation as a potential entry point for long-term recovery, the community remains deeply divided, with many actively debating whether the leadership change signals a strategic turnaround or continued brand decline.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently experiencing extreme volatility as market participants debate whether the recent aggressive rally is a sustainable trend or a blow-off top fueled by AI exuberance. While some traders are aggressively adding to leveraged short positions, anticipating a technical correction, others remain focused on the potential for continued momentum as the sector remains the primary leader in an AI-concentrated market.

8i Acquisition 2 Corp. is a blank check company. Its purpose is to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The company was founded on January 21, 2021 and is headquartered in Singapore.

Euda Health Holdings Limited

Euda Health Holdings is currently trending as the community monitors its volatile price action and ongoing reverse split activity, with active discussions focused on its low-float structure and potential for momentum-driven moves. Traders are heavily debating the stock's susceptibility to short squeezes and pump-and-dump patterns, with many closely watching for catalysts that could trigger a reversal from recent lows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS

Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...

Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...

Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday

Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...

Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research

Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average   - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The unit is selling the voucher for $205 million, the company said.&nbsp;</li><li>20% of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.&nbsp;</li><li>The voucher was issued upon approval of ZYCUBO last month for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients.</li></ul>Shares of Fortress Biotech, Inc. (FBIO) rose 10% on Monday after the company announced that its majority-owned unit will sell its voucher for expedited review of a drug application by the U.S. Food and Drug Administration (FDA) for $205 million.Fortress <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/02/23/3242714/28889/en/UPDATE-Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html">said</a> that its unit Cyprium Therapeutics, Inc. has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Sentynl Therapeutics, Inc, a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences Limited.Twenty percent of the proceeds from the voucher sale is owed to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the company said, while also noting that the transaction is subject to customary closing conditions.The PRV program aims to incentivize drug development for rare pediatric diseases.<h2 class="st-heading-2">Cyprium, Sentynl History</h2>Sentynl took over responsibility for the development and commercialization of the drug ZYCUBO from Cyprium in December 2023. Zycubo was approved by the FDA in January for the treatment of Menkes disease, a rare genetic disorder, in pediatric patients. The voucher was issued upon approval of ZYCUBO.Fortress said on Monday that it remains eligible to receive tiered royalties on net sales of ZYCUBO and up to $129 million in aggregate development and sales milestones from Sentynl.“With the PRV sale and three FDA approvals received in the last 15 months for Emrosi, UNLOXCYT, and ZYCUBO, in addition to the recent sale of our former subsidiary Checkpoint Therapeutics to Sun Pharma, we believe that we are well positioned to continue to execute on our portfolio,” said Fortress CEO Lindsay A. Rosenwald.<h2 class="st-heading-2">Cyprium’s Pipeline</h2>Menkes disease is a rare genetic disorder leading to impaired copper transport throughout the body. It causes low copper levels in the brain, resulting in rapid neurodegeneration, seizures, and more. Cyprium is also developing a gene therapy to deliver working copies of the copper transporter that is defective in patients with Menkes disease, and to be used in combination with ZYCUBO. The gene therapy is currently in pre-clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around FBIO shares jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user expressed optimism for the gene therapy trial data sending the stock skyrocketing. In the short term, the user expects the company to be buoyed by royalties from its Menkes drug, and in the long term, from the gene therapy.<stembedurl>https://www.stocktwits.com/buymoremakemore/message/645614222</stembedurl><a href="https://stocktwits.com/symbol/FBIO">FBIO stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gossamer-bio-stock-plummeted-today-what-is-behind-the-crash/cZRtwTVR4ym">Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy 

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 

Equity

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics. 


Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Current Price	$2.25
Prev Close	$2.25
Open	$2.25
Dividend Yield	0.00%
50-Day Moving Average	$2.99
Beta	0.93
Avg. Volume	467,352.50
PE Ratio	-18.83

52-Week High	$4.53
52-Week Low	$1.60
Market Capitalization	$72.46M
EPS (Annual)	-$0.0674
Price to Book	1.42
Revenue Per Employee	$811,051.28

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FBIO News

FBIOFortress Biotech Inc